# Lantheus Holdings, Inc. (LNTH)

> Source: Nexqual · https://nexqual.com/LNTH · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Lantheus Holdings, Inc. (LNTH), nexqual.com/LNTH" · informational, not investment advice.

**Price:** USD 100.1 (-0.14% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 100.24 · day 99.75–100.34 · 52w 50.16–111.86 · market cap $6.54B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.56B, net income $275M (17.7% margin), free cash flow $388M (SEC filings).
- Valuation: P/E 23.7x (avg 17.8x at the last 3 fiscal year-ends), EV/EBITDA 16.7x, net cash $22.2M.
- 1 of 80 tracked superinvestors hold LNTH (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Hold (mean 2.70 on a 1–5 scale) (10 analysts), mean target USD 106.99 (range 102.5–115).
- Total return with dividends: 1Y +77.1% vs S&P 500 +14.9%; 5Y +340.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.29, revenue estimate $358M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $425M | $935M | $1.30B | $1.53B | $1.54B | $1.56B |
| Gross profit | $188M | $582M | $710M | $988M | $942M | — |
| Operating income | -$60.8M | $36.2M | $365M | $457M | $311M | $302M |
| Net income | -$71.3M | $28.1M | $327M | $312M | $234M | $275M |
| EPS (diluted) | -$1.06 | $0.40 | $4.65 | $4.36 | $3.41 | — |
| Free cash flow | $53.9M | $21.8M | $260M | $493M | $354M | $388M |
| Gross margin | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% | — |
| Operating margin | -14.3% | 3.9% | 28.1% | 29.8% | 20.2% | 19.4% |
| Net margin | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% | 17.7% |
| Revenue growth | +25.3% | +119.9% | +38.6% | +18.3% | +0.5% | — |
| Cash + short-term investments | $98.5M | $416M | $714M | $913M | $359M | — |
| Total debt | $175M | $558M | $562M | $566M | $569M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 23.7x · P/S 4.2x · EV/EBITDA 16.7x · EV/Sales 4.2x · P/FCF 16.9x · P/B 5.0x · FCF yield 5.93% · Earnings yield 4.21% · Net cash $22.2M · EV $6.51B
P/E at fiscal year-ends: Dec 2025 19.5x, Dec 2024 20.5x, Dec 2023 13.3x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold LNTH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | <0.01% | $888K | New position |

## Analysts
Consensus Hold (mean 2.70 on a 1–5 scale), 10 analysts; mean target USD 106.99 (low 102.5, high 115).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Mizuho | Downgrade | Outperform → Neutral | $115 → $109 |
| 2026-08-04 | Truist Securities | Downgrade | Buy → Hold | $125 → $102.5 |
| 2026-08-04 | CJS Securities | Downgrade | Market Outperform → Market Perform |  |
| 2026-08-03 | William Blair | Downgrade | Outperform → Market Perform |  |
| 2026-08-03 | TD Cowen | Downgrade | Buy → Hold | $110 → $102.5 |
| 2026-07-29 | Mizuho | Target lowered | Outperform | $120 → $115 |
| 2026-07-16 | Truist Securities | Target raised | Buy | $115 → $125 |
| 2026-07-15 | Mizuho | Target raised | Outperform | $115 → $120 |
| 2026-07-09 | B. Riley Securities | Target raised | Buy | $97 → $129 |
| 2026-06-29 | Citizens | Reiterated | Market Outperform | $115 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +77.1% | +340.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +77.5% | +34.4% |
| Volatility (annualized) | 32.4% | 56.6% |
| Max drawdown | -12.8% (Oct 2025→Nov 2025) | -59.2% (Jul 2024→Sep 2025) |

## Peers (Drug Manufacturers - Specialty & Generic)
KNSA (Kiniksa Pharmaceuticals Interna) USD 80.79 +1.37% · HIMS (Hims & Hers Health, Inc.) USD 29.13 -0.27% · AMRX (Amneal Pharmaceuticals, Inc.) USD 20.48 +1.39% · ALKS (Alkermes plc) USD 44.18 +1.61% · RGC (Regencell Bioscience Holdings L) USD 9.81 -9.17% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.33 +1.55%

## More
Full page: https://nexqual.com/LNTH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name LNTH in their own reports (relationship from LNTH's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Radiopharm Theranostics Ltd (RADX) | 20-F 2026-09-30 | "into an equity agreement with Lantheus Omega, LLC ("Lantheus Omega"), a wholly-owned subsidiary of Lantheus Holdings, Inc." |
| partner | Perspective Therapeutics, Inc. (CATX) | 10-K 2026-03-16 | "In January 2024, we announced we had entered into a strategic agreement with an affiliate of Lantheus Holdings, Inc. (Lantheus) whereby in exchange for an upfront payment of $28 million (less certain …" |
| partner | AC Immune SA (ACIU) | 20-F 2026-03-13 | "If we fail to maintain our current strategic relationships with Eli Lilly and Company (Lilly), Janssen Pharmaceuticals Inc. (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson,…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.29 | $1.29 | +0.3% | $358.1M | 9 |
| Next quarter (ends 2026-12-31) | $1.37 | $1.36 | +0.3% | $368.1M | 9 |
| Current fiscal year (ends 2026-12-31) | $5.36 | $5.37 | -0.1% | $1.47B | 9 |
| Next fiscal year (ends 2027-12-31) | $6.38 | $6.35 | +0.5% | $1.65B | 10 |